7.97
0.14 (1.79%)
| Previous Close | 7.83 |
| Open | 7.83 |
| Volume | 2,057,323 |
| Avg. Volume (3M) | 2,715,815 |
| Market Cap | 1,054,300,160 |
| Price / Sales | 34.86 |
| Price / Book | 6.34 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -788.76% |
| Diluted EPS (TTM) | -1.20 |
| Quarterly Revenue Growth (YOY) | -16.70% |
| Total Debt/Equity (MRQ) | 22.16% |
| Current Ratio (MRQ) | 6.26 |
| Operating Cash Flow (TTM) | -135.34 M |
| Levered Free Cash Flow (TTM) | -67.25 M |
| Return on Assets (TTM) | -26.79% |
| Return on Equity (TTM) | -61.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tango Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 12.59% |
| % Held by Institutions | 97.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Boxer Capital Management, Llc | 30 Jun 2025 | 9,771,485 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (Guggenheim, 50.57%) | Buy |
| Median | 11.50 (44.29%) | |
| Low | 11.00 (Piper Sandler, 38.02%) | Buy |
| Average | 11.50 (44.29%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 24 Oct 2025 | 12.00 (50.56%) | Buy | 7.50 |
| Piper Sandler | 19 Aug 2025 | 11.00 (38.02%) | Buy | 6.96 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Nov 2025 | Announcement | Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights |
| 29 Oct 2025 | Announcement | Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 |
| 23 Oct 2025 | Announcement | Tango Therapeutics Announces $225 Million Financing |
| 23 Oct 2025 | Announcement | Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers |
| 06 Oct 2025 | Announcement | Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 |
| 26 Aug 2025 | Announcement | Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |